A follow-up analysis of patients enrolled in Phase I / II multi-center trial for diffuse large B-cell lymphoma (DLBCL) reported 51% of patients receiving an anti-CD19 chimeric antigen receptor (CAR T) called axi-cel were still alive two years post-treatment.
All news from Hematology & Oncology
Researchers from the Princess Máxima Center for Pediatric Oncology have shown that the number of mutations in healthy and leukemic blood stem cells does not differ. Rather, the location of DNA mutations is relevant.
Stem cell transplantation is effective against leukemia. In many cases, however, the transferred immune cells of the donor also attack the recipients' healthy tissue—often with fatal consequences. Researchers at the University of Zurich have now identified a molecule that plays a key role in this process.
Stem-cell transplantation is an effective form of therapy to fight leukemia. In many cases, however, the transferred immune cells of the donor also attack the recipients' healthy tissue often with fatal consequences.
The U.S. Food and Drug Administration today granted accelerated approval to Vitrakvi (larotrectinib), a treatment for adult and pediatric patients whose cancers have a specific genetic feature (biomarker). This is the second time the agency has approved a cancer treatment based on a common biomarker across different types of tumors rather than the location in the body where the tumor originated.
In a study tracking the severe crisis pain of sickle cell disease and its management in 73 adults over a period of a year, Johns Hopkins researchers found that even among those on high doses of daily at-home opioids, a persistent subset was more likely to seek emergency hospital care for crisis pain and was less likely to have the pain controlled by intensive treatment.
A $625 million False Claims Act settlement, which is one the largest ever, includes a reward of roughly $100 million that is being split up among a trio of whistleblowers who exposed an illegal cancer drug scheme perpetrated by AmerisourceBergen Corporation, the major US drug wholesaler.
The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are 75 years of age or older
The US Food and Drug Administration (FDA) has approved emapalumab (Gamifant, Novimmune) for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance to conventional HLH therapy.
Scientists at the University of Southampton have developed a new antibody that could hold the key to unlocking cancer's defence against the body's immune system. In a new study published in Immunity, the team, which is based at the Centre for Cancer Immunology, engineered antibodies to target a particularly significant immune receptor called 4-1BB, which can activate killer T-cells to find and destroy cancer cells.
A triple therapy combining two immune checkpoint inhibitors (ICPIs) with the standard-of-care chemotherapy, a hypomethylating agent called azacitidine, has shown promising results for treatment of relapsed or refractory acute myeloid leukemia (AML), according to findings from a Phase II study at The University of Texas MD Anderson Cancer Center.